Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 3
2000 5
2001 7
2002 1
2003 3
2006 2
2009 1
2010 1
2013 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

24 results
Results by year
Filters applied: . Clear all
Page 1
Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia.
Barone FC, Irving EA, Ray AM, Lee JC, Kassis S, Kumar S, Badger AM, Legos JJ, Erhardt JA, Ohlstein EH, Hunter AJ, Harrison DC, Philpott K, Smith BR, Adams JL, Parsons AA. Barone FC, et al. Among authors: erhardt ja. Med Res Rev. 2001 Mar;21(2):129-45. doi: 10.1002/1098-1128(200103)21:2<129::aid-med1003>;2-h. Med Res Rev. 2001. PMID: 11223862 Review.
Benzofuran-substituted urea derivatives as novel P2Y(1) receptor antagonists.
Thalji RK, Aiyar N, Davenport EA, Erhardt JA, Kallal LA, Morrow DM, Senadhi S, Burns-Kurtis CL, Marino JP Jr. Thalji RK, et al. Among authors: erhardt ja. Bioorg Med Chem Lett. 2010 Jul 15;20(14):4104-7. doi: 10.1016/j.bmcl.2010.05.072. Epub 2010 Jun 9. Bioorg Med Chem Lett. 2010. PMID: 20542694
Caspase inhibitors as neuroprotective agents.
Legos JJ, Lee D, Erhardt JA. Legos JJ, et al. Among authors: erhardt ja. Expert Opin Emerg Drugs. 2001 Apr;6(1):81-94. doi: 10.1517/14728214.6.1.81. Expert Opin Emerg Drugs. 2001. PMID: 15989498
Expression of PEP-19 inhibits apoptosis in PC12 cells.
Erhardt JA, Legos JJ, Johanson RA, Slemmon JR, Wang X. Erhardt JA, et al. Neuroreport. 2000 Nov 27;11(17):3719-23. doi: 10.1097/00001756-200011270-00026. Neuroreport. 2000. PMID: 11117479
Caspase 3 activation is essential for neuroprotection in preconditioning.
McLaughlin B, Hartnett KA, Erhardt JA, Legos JJ, White RF, Barone FC, Aizenman E. McLaughlin B, et al. Among authors: erhardt ja. Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):715-20. doi: 10.1073/pnas.0232966100. Epub 2003 Jan 9. Proc Natl Acad Sci U S A. 2003. PMID: 12522260 Free PMC article.
Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.
King AJ, Arnone MR, Bleam MR, Moss KG, Yang J, Fedorowicz KE, Smitheman KN, Erhardt JA, Hughes-Earle A, Kane-Carson LS, Sinnamon RH, Qi H, Rheault TR, Uehling DE, Laquerre SG. King AJ, et al. Among authors: erhardt ja. PLoS One. 2013 Jul 3;8(7):e67583. doi: 10.1371/journal.pone.0067583. Print 2013. PLoS One. 2013. PMID: 23844038 Free PMC article.
24 results